All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On 25th July 2017, Joseph M Brandwein, member of our North America Steering Committee, from the University of Alberta, Edmonton, Canada, et al. published revised clinical practice guidelines for the management of Acute Myeloid Leukemia (AML) in patients age 60 years and over in the American Journal of Blood Research.
Based on recent studies, Brandwein et al. made the following recommendations:
Brandwein et al. concluded by encouraging older patients to be enrolled in clinical trial studies, which they hope would lead to “new standards of care which would necessitate further revisions to the guidelines” in the future.
The treatment of acute myeloid leukemia (AML) in older patients is undergoing rapid changes, with a number of important publications in the past five years. Because of this, a group of Canadian leukemia experts has produced an update to the Canadian Consensus Guidelines that were published in 2013, with several new agents recommended, subject to availability. Recent studies have supported the survival benefit of induction chemotherapy for patients under age 80, except those with major co-morbidities or those with adverse risk cytogenetics who are not candidates for allogeneic hematopoietic stem cell transplantation (HSCT). Midostaurin should be added to induction therapy for patients up to age 70 with a FLT3 mutation, and gemtuzumab ozogamicin for de novo AML up to age 70 with favorable or intermediate risk cytogenetics. Daunorubicin 60 mg/m2 is the recommended dose for 3+7 induction therapy. Acute promyelocytic leukemia should be treated with arsenic trioxide plus all-trans retinoic acid, regardless of age, with cytotoxic therapy added upfront only for those with initial white blood count > 10. HSCT may be considered for selected suitable patients up to age 70-75. Haploidentical donor transplants may be considered for older patients. For non-induction candidates, azacitidine is recommended for those with adverse risk cytogenetics, while either a hypomethylating agent (HMA) or low-dose cytarabine can be used for others. HMA may also be used for relapsed/refractory disease after chemotherapy. For patients with secondary AML, CPX-351 is recommended for fit patients age 60-75.
Since the publication of these guidelines in 2013, the approach to older patients with AML has evolved considerably. First, there has been a progressively wider acceptance of the notion that selected older patients with AML are candidates for aggressive AML treatment, as well as for allogeneic alloSCT.2,3 Second, the completion and publication of several clinical trials (and of subsequent updates) have clarified the approach to older patients with AML receiving induction therapy4,5,6, as well as to those deemed not suitable for induction chemotherapy.7 Third, a consensus approach to low- and high-risk APL has been defined.8,9,10,11 Fourth, the role of comprehensive molecular profiling in prognostication in AML has been refined.12 And fifth, a number of recent clinical trials and drug approvals13 have suggested alternative approaches to the treatment of AML in the older patient.
Due to the above changes in the Canadian AML treatment landscape, the Canadian expert panel met in 2016 to develop revised guidelines for the treatment of AML in the older patient, which were published in 2017.14 These new guidelines recommend the consideration of induction chemotherapy for suitably fit patients up to age 80, the consideration of clinical trial approaches, if available, and include strategies that are not necessarily funded in all (or any) Canadian jurisdictions. As in the 2013 guidelines, specific treatment algorithms are suggested:
In low/intermediate risk APL, a chemo-free ATRA/ATO approach8,9 is recommended. In high risk APL, the idarubicin/ATRA/ATO APML4 protocol10,11 is recommended.
For induction candidates with non-APL AML, the addition of midostaurin to standard 3+7 induction therapy for patients with a FLT3 mutation up to age 70; the addition of gemtuzumab ozogamicin to 3+7 induction chemotherapy up to age 70 with favourable or intermediate risk cytogenetics; or the use of CPX-351 for patients with sAML aged 60-75, are recommended.
For patients with non-APL AML not eligible for induction chemotherapy, azacitidine and low dose cytarabine are considered equivalent in cases with standard risk cytogenetics, in the absence of myelodysplasia-related morphologic features. If the latter features are present, azacitidine is favoured. Azacitidine is recommended in cases with adverse risk cytogenetics.
While other recent guideline revisions such as ELN 201715 and NCCN16 also have incorporated recent developments in AML treatment, the Canadian consensus guidelines differ somewhat in that they are structured as targeted answers to selected questions, focus primarily on changes that have occurred since the 2013 version, and present treatment options in practical terms as simple, user-friendly algorithms shaped by expert opinion.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox